Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.44 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.42 |
| ▸ | PPID | Q08752 | 1/20 | 0.42 |
| ▸ | PRCP | P42785 | 4/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14610872 | 0.86 | HRH3 (0.48) | HRH3EPHX2RIPK1PPIDPRCP | |
| SCHEMBL14557696 | 0.86 | EPHX2 (0.43) | EPHX2RIPK1PPIDMEN1KMT2A | |
| SCHEMBL14569486 | 0.84 | HRH3 (0.50) | HRH3EPHX2RIPK1PPIDPRCP | |
| SCHEMBL20905412 | 0.83 | RIPK1 (0.59) | EPHX2RIPK1PPIDADAM17 | |
| SCHEMBL14610878 | 0.83 | RIPK1 (0.46) | EPHX2RIPK1PPIDMEN1KMT2A | |
| SCHEMBL14611259 | 0.77 | RIPK1 (0.44) | EPHX2RIPK1PPIDMEN1KMT2A | |
| SCHEMBL25884649 | 0.76 | EPHX2 (0.63) | EPHX2RIPK1PPIDPRCPMEN1 | |
| SCHEMBL14557693 | 0.75 | KDM4E (0.41) | RIPK1MEN1KMT2ANPSR1HPGD | |
| SCHEMBL14557708 | 0.75 | EPHX2 (0.41) | EPHX2RIPK1PPIDADAM17 | |
| SCHEMBL14557703 | 0.74 | ROCK2 (0.40) | HRH3RIPK1NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070054909-A1 | VLA-4 inhibitor compounds | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-03-08 | — | — | US | disclosed |
| US-7179819-B2 | VLA-4 inhibitor compounds | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-02-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070054909-A1 | VLA-4 inhibitor compounds | VCAM1, ITGB4, ICAM1 | HRH3 1894/4885EPHX2 3415/4885RIPK1 4081/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.